Published in PLoS One on April 23, 2015
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. J Virol (2016) 0.78
A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Sci Rep (2016) 0.76
A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines. Hum Vaccin Immunother (2017) 0.75
Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. MBio (2017) 0.75
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol (1994) 4.29
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 4.10
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule. J Biol Chem (1971) 3.27
Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA (2008) 2.88
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A (2006) 2.64
ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. J Biol Chem (1980) 2.41
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature (1987) 2.00
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Cross-roads in the classification of papillomaviruses. Virology (2013) 1.87
A simple, rapid, high-fidelity and cost-effective PCR-based two-step DNA synthesis method for long gene sequences. Nucleic Acids Res (2004) 1.86
MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol (1992) 1.71
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol (1999) 1.66
Immunobiology of HPV and HPV vaccines. Gynecol Oncol (2008) 1.66
A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine (2005) 1.38
Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol (2009) 1.35
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One (2011) 1.28
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27
Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS One (2009) 1.25
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J Biol Chem (2004) 1.24
Diseases associated with human papillomavirus infection. Virology (2013) 1.18
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
Hepatitis B virus core particles as epitope carriers. Intervirology (1995) 1.09
Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr (2001) 1.08
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
L2, the minor capsid protein of papillomavirus. Virology (2013) 1.07
VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One (2012) 1.07
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol (2004) 1.06
Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol (2013) 1.06
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05
The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology (2010) 1.04
A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine (2013) 1.02
A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology (2001) 1.00
[Construction and application of an Escherichia coli high effective expression vector with an enhancer]. Sheng Wu Gong Cheng Xue Bao (2000) 1.00
A quantitative description of in vitro assembly of human papillomavirus 16 virus-like particles. J Mol Biol (2008) 0.98
Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA. Infect Immun (1999) 0.98
Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. J Immunol Methods (1995) 0.96
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics (2014) 0.91
Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe. Acta Dermatovenerol Alp Pannonica Adriat (2013) 0.90
Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol J (2009) 0.88
Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. Virology (2012) 0.87
Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. Vaccine (2014) 0.81
Development of human papillomavirus chimaeric L1/L2 candidate vaccines. Arch Virol (2013) 0.81
A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types. PLoS One (2014) 0.78